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Education and debate
Forest plots: trying to see the wood and the trees
Steff Lewis, Mike Clarke
Few systematic reviews containing meta›analyses are
complete without a forest plot. But what are forest
plots, and where did they come from?
What is a forest plot?
In a typical forest plot, the results of component stud›
ies are shown as squares centred on the point estimate
of the result of each study. A horizontal line runs
through the square to show its confidence interval—
usually, but not always, a 95% confidence interval. The
overall estimate from the meta›analysis and its
confidence interval are put at the bottom, represented
as a diamond. The centre of the diamond represents
the pooled point estimate, and its horizontal tips
represent the confidence interval. Significance is
achieved at the set level if the diamond is clear of the
line of no effect.
The plot allows readers to see the information from
the individual studies that went into the meta›analysis
at a glance. It provides a simple visual representation of
the amount of variation between the results of the
studies, as well as an estimate of the overall result of all
the studies together. Forest plots increasingly feature in
medical journals, and the growth of the Cochrane Col›
laboration has seen the publication of thousands in
recent years.1
History
The origin of forest plots goes back at least to the
1970s. Freiman et al displayed the results of several
studies with horizontal lines showing the confidence
interval for each study and a mark to show the point
estimate. This study was not a meta›analysis, and the
results of the individual studies were therefore not
combined into an overall result.2 In 1982, Lewis and
Ellis produced a similar plot but this time for a
meta›analysis, and they put the overall effect on the
bottom of the plot (fig 1 ).3 However, smaller studies,
with less precise estimates of effect, had larger
confidence intervals and, perversely, were the most
noticeable on the plots.
Means of focusing attention on the larger, more
precise, studies were sought. Replacement of the mark
with a square whose size was proportional to the preci›
sion of the estimate may have been first suggested by
Stephen Evans at a Royal Statistical Society medical
section meeting at the London School of Hygiene and
Tropical Medicine in 1983 (S Evans, personal commu›
nication). He based the idea on modified box plots.4
Ideas such as radial plots were also proposed.5 6
The first meta›analyses to include squares of differ›
ent sizes to show the positions of the point estimates
were probably those produced by the Clinical Trial
Service Unit in Oxford in the 1998 overview of the
prevention of vascular disease by antiplatelet therapy.7
The area of each square was proportional to the weight
that the individual study contributed to the meta›
analysis.
Summary points
Forest plots show the information from the
individual studies that went into the meta›analysis
at a glance
They show the amount of variation between the
studies and an estimate of the overall result
Forest plots, in various forms, have been
published for about 20 years
During this time, they have been improved, but it
is still not easy to draw them in most standard
computer packages
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Fig 1 First use of forest plot for meta›analysis of effect of â blockers on mortality3
(reproduced with permission from Physicians World/Thomson Healthcare, Secaucus, NJ)
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We have updated the original Lewis and Ellis plot3
to show how it might look in the modern style (fig 2 ).
We obtained data for most of the component studies
from a subsequent paper.8 In the 1980s, no standard
computer packages could easily produce these plots,
and they came from specially produced computer
programs. Even now, most standard statistical packages
cannot easily produce such a plot.
Why a forest plot?
The plot was not called a “forest plot” in print for some
time, and the origins of this title are obscured by
history and myth. At the September 1990 meeting of
the breast cancer overview, Richard Peto jokingly men›
tioned that the plot was named after the breast cancer
researcher Pat Forrest, and, at times, the name has been
spelt “forrest plot.” However, the phrase actually origi›
nates from the idea that the typical plot appears as a
forest of lines. A contender for the first use of the name
“forest plot” in print is a review of nursing
interventions for pain that was published in 1996.9 An
abstract at the Cochrane colloquium later that year
also used this name.10 We would welcome suggestions
of precedents to these uses or any other versions of this
brief history of the plot.
We thank Jon Godwin for preparing figure 2.
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Fig 2 Updated version of Lewis and Ellis’s original plot (fig 1 ) showing effect of â blockers
on mortality
A memorable patient
A chandelier and a vat of custard
It was a busy Friday night in casualty. We were one senior house
officer down and there had been a major accident on a nearby
main road. All of us had been looking after seriously injured
patients for the preceding couple of hours—not all of them had
survived, and emotions were running high. During that time, the
backlog of minor injuries had built up to a six hour wait, and
tempers were fraying in the waiting room. The nurses were
fielding angry patients, often with trivial injuries, and were
desperate for one of us to come and help.
I returned to the minor side to start clearing the backlog as
soon as possible. I was in a superefficient and slightly
short›tempered mood—didn’t they realise that we had to deal
with far more important things than cut fingers or drunks? I
picked the next card out of the box and went to the cubicle.
With barely a glance at the patient I said brusquely, “Well,
what’s the matter then?” A middle aged man looked back at me
and said, in a nonchalant tone, “I was preparing for my usual
Friday night sexual activity when the chandelier broke, and I fell
into the vat of custard.”
It took a second or two for me to realise what he’d said. I
looked up at him in disbelief. “Really?” I asked. “No,” he said, “but
I’ve been sitting in the waiting room for two hours trying to pluck
up the courage to say that.”
As a grin broke over my face, I asked what had really
happened, and he told me what he had done. As I treated him, I
relaxed and chatted to him as a real person, not a patient.
I spent the rest of the shift smiling. It inspired me to think that
someone faced with a long wait had thought up something like
that, and kept it in his mind, without getting annoyed or
impatient. He changed my perspective, brightened up my
evening, and reminded me of the fact that people, not patients,
were in the waiting room.
I have long since forgotten his name, but I still think about him
when I’m having a bad day.
Katherine Whybrew GP registrar, 19 Beaumont Street Surgery,
Oxford
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